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Background: Primary pulmonary enteric adenocarcinoma (PEAC) is defined as a pulmonary adenocarcinoma with a
predominant component of intestinal differentiation and tumor cells positive for at least one intestinal marker. The
aim of the present study was the molecular and histological characterization of a PEAC from a patient with two
other family members affected by similar lung tumors, which has never been reported before.
Findings: We evaluated the molecular characteristics of the proband’s PEAC by using a previously validated
47-microRNA (miRNA) cancer-specific array and a predictive method to estimate tissue-of-origin probabilities.
Immunohistochemical (IHC) staining for thyroid transcription factor (TTF-1), napsin A, caudal-related homeobox 2
(CDX2), cytokeratins, and mucins, as well as mutational analyses for epidermal growth factor receptor (EGFR), Kirsten
rat sarcoma viral oncogene homolog (KRAS), and anaplastic lymphoma kinase (ALK) were performed on formalin-
fixed, paraffin-embedded (FFPE) tissues.
The occurrence of PEAC in two family members was associated with similar clinicopathological features (age at
diagnosis, smoking habit, tumor localization, multiple colonic polyps), histologic findings (TTF-1 negativity and
CDX2 positivity), and genetic findings (KRAS (Gly12Asp) mutation, but no EGFR/ALK aberrations). miRNA profiling
revealed similarities with non-small cell lung cancer (NSCLC; 75.98 %) and some overlap with pancreatic ductal
adenocarcinoma (PDAC; 23.34 %), but not with colorectal cancer (CRC; less than 0.5 %). Notably, these PEACs share
key PDAC-associated miRNAs associated with tumor aggressiveness (miR-31*/-126*/-506/-508-3p/-514).
Conclusions: We describe for the first time PEAC in members from the same family, associated with similar clinical
and genetic features. miRNA profiling of the PEAC resembled a NSCLC signature, with partial overlap to a PDAC
pattern. This could explain its aggressive behavior and therefore help to guide future tailored-therapeutic
approaches.
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Introduction
Primary pulmonary enteric adenocarcinoma (PEAC) is
defined as a pulmonary adenocarcinoma with a predom-
inant component (>50 %) of intestinal differentiation
and with tumor cells positive for at least one intestinal
marker such as caudal-related homeobox 2 (CDX2),
CK20, or MUC2 [1]. It was first described in 1991 [2],
and a total of 31 cases have been reported in the litera-
ture [2–13]. In the International Multidisciplinary Clas-
sification of Lung Adenocarcinoma (2011), PEAC was
classified as a rare variant of invasive adenocarcinoma
[1]. The overlap between PEAC and metastases from
other tumors (such as colorectal cancer (CRC)) repre-
sents an important diagnostic problem [2–13]. Several
studies have demonstrated the ability of microRNA
(miRNA) profiling for the identification of the tissue of
origin for ambiguous cancers, assisting in the diagnosis
of carcinomas of unknown origin [14, 15].
In the present study, we performed miRNA profiling
in conjunction with immunohistochemical (IHC) and
genetic analyses on a formalin-fixed, paraffin-embedded
(FFPE) tissue from a patient affected by PEAC. Notably,
this patient had a sister and a brother who were also af-
fected by PEAC, and we describe the main clinicopatho-
logical findings in these family members.
Materials and methods
Patients
The proband was a 68-year-old male, ex-smoker, with
no history of malignancy or relevant comorbidities.
Computed tomography (CT) and positron emission
tomography ([18F]FDG-PET) showed a 3.5-cm nodule in
the right lower lobe with high glucose uptake. Lobec-
tomy revealed a stage-IIA non-small cell lung cancer
(NSCLC) with PEAC histology. Colonoscopy showed
multiple benign polyps, but excluded primary CRC.
Post-operative CT and [18F]FDG-PET revealed a small
(8 mm) osteolytic area in the left hip bone. Considering
the predominant component of intestinal differentiation,
the patient was treated with XELOX (capecitabine +
oxaliplatin) and a bisphosphonate, though with a very
short CT scan re-evaluation, which after 2 cycles of
chemotherapy showed progression of the bone lesion
(2 cm). Consequently, the patient underwent surgical re-
moval of this unique bone lesion, which was confirmed
histologically as a PEAC metastasis. After 4 months, the
patient relapsed with multiple bone metastases and
underwent 4 cycles of carboplatin + pemetrexed which
did not arrest tumor progression. Subsequent chemo-
therapy with docetaxel resulted in disease stability after
2 cycles.
Similarly, the 71-year-old proband’s sister underwent
lung lobectomy revealing a stage-IB PEAC (Table 1),which progressed in 12 months with lung and adrenal
gland metastases, but after 6 cycles of carboplatin +
pemetrexed, followed by pemetrexed alone, became
stable. Another brother (72 years old) presented with an
advanced stage lung tumor (pleural effusion and mul-
tiple lytic bone metastases) and succumbed 1 month
after diagnosis.
IHC and genetic and microarray analyses
The IHC analysis evaluated thyroid transcription factor
(TTF-1), napsin A, cytokeratins (CK7/CK20), CDX-2,
and mucins (MUC1/MUC2/MUC5AC/MUC6). For the
genetic analyses, the neoplastic area was macro-
dissected using a parallel hematoxylin and eosin (H&E)
slide as a reference, with subsequent DNA/RNA isola-
tion from samples with >80 % tumor infiltration. Epider-
mal growth factor receptor (EGFR) and Kirsten rat
sarcoma viral oncogene homolog (KRAS) analyses were
performed by PCR and direct sequencing, respectively.
Anaplastic lymphoma kinase (ALK) status was studied
by fluorescence in situ hybridization. Microsatellite in-
stability (MSI) was evaluated by multiplex amplification
and sequencing.
miRNA profiling was performed using the Agilent
Human miRNA microarray v.2 (#G4470B; Agilent Tech-
nologies, Santa Clara, CA, USA). The Feature Extraction
10.7 and GeneSpring GX13 software were used to
analyze the microarray raw, and we applied a previously
validated method to estimate tissue-of-origin probabil-
ities [15]. Manhattan correlation was used as a measure
of similarity.
No samples for further pathological and genetic ana-
lyses were available from the proband’s sister, while cyto-
logical specimens of the proband’s brother were available
to evaluate TTF-1, CDX-2, CK7, CK20, and for PCR
analysis of selected miRNAs.
Further details on the analyses of EGFR, KRAS, ALK,
MSI, and miRNA-PCR are in Additional file 1.
Results
Clinicopathological characteristics
The occurrence of PEAC in the proband and his sister
was associated with similar clinicopathological features,
summarized in Table 1, such as comparable age at diag-
nosis, smoking history, and identical localization of the
tumor. Colonoscopy in both cases revealed multiple be-
nign polyps and diverticulosis of the sigmoid colon. Not-
ably, the proband’s brother had also comparable age and
smoking history, but the dramatic history of his disease
precluded additional analyses.
Histology, genetics, and miRNA profiling
Macroscopically, a well-circumscribed lung nodule with
a maximum diameter of 3.5 cm was found in both cases.
Table 1 Demographic and disease characteristics of two patients affected by PEAC within one family. The familial aggregation of
PEAC was associated with similar clinicopathological features (age at diagnosis, smoking habit, tumor localization, multiple colon
polyps), histologic findings (IHC staining negative for TTF-1 and positive for CDX2), and genetic findings (KRAS(Gly12Asp) mutation
but no EGFR/ALK aberrations)
Characteristic Proband His sister
General
Age at diagnosis (years) 68 71
Smoking habit Yes Yes
Primary localization Lung: right/lower lobe Lung: right/lower lobe
Colonoscopy Multiple benign polyps (N < 10), diverticulosis Multiple benign polyps (N < 10), diverticulosis
Radical surgery (R0) Yes Yes
Metastases/DFS (months) Bone/1.5 Lung, adrenal glands/12
Histological findings Primary tumor Bone metastasis
Histology PEAC PEAC PEAC
Stage (pTNM) pT2apN1 pT2apN0
IHC analyses
TTF-1 NEG NEG NEG
Napsin A NEG NA NA
CK7 POS NA NEG
CK20 NEG NA POS
CDX2 POS POS POS
MUC1 POS NA NA
MUC2 NEG NA NA
MUC5AC POS NA NA
MUC6 NEG NA NA
Microsatellite instability MSS phenotype NA NA
Genetics
EGFR Wild type NA Wild type
KRAS Gly12Asp mutation Gly12Asp mutation Gly12Asp mutation
ALK Wild type NA Wild type
Abbreviations: ALK anaplastic lymphoma kinase, CDX2 caudal-related homeobox 2, CK7 cytokeratonin-7, CK20 cytokeratonin-20, DFS disease-free survival, EGFR
epidermal growth factor receptor, IHC immunohistochemistry, KRAS Kirsten rat sarcoma viral oncogene homolog, MUC1 mucin 1, MUC2 mucin 2, MUC5AC mucin
5A, MUC6 mucin 6, NA non available, NEG negative, PEAC primary pulmonary enteric adenocarcinoma, POS positive, TTF-1 thyroid transcription factor, pTNM
pathological tumor-node-metastasis
Garajová et al. Clinical Epigenetics  (2015) 7:129 Page 3 of 7Microscopically, the nodule was composed of medium-
to-large complex glands, and tumor cells were cuboidal
to tall columnar with a brush border and eosinophilic
cytoplasm. Areas of irregular necrosis were present, as
previously described [2]. H&E revealed two different
phenotypes in the lung lesion of the proband: NSCLC
(30 %) and PEAC (70 %; Fig. 1). Expression of TTF-1
and CDX2 are associated with NSCLC and PEAC, re-
spectively. Similar results were observed in the cyto-
logical specimens of the proband’s brother (Additional
file 2: Figure S1). Moreover, we observed strong coex-
pression of MUC1 and MUC5AC in the areas with
PEAC histology, while in the same areas, we did not de-
tect MUC2. In particular, the panel 4 of the Fig. 1 sum-
marizes the MUCs expression compared to the subtypes
of pancreatic intraductal papillary mucinous neoplasms(IPMNs). Considering the intestinal-type pulmonary
histology and multiple colonic polyps, we evaluated on
the tissue of the proband the MSI markers, which sug-
gested the absence of microsatellite instability (MSS
phenotype). KRAS (Gly12Asp) mutations but no EGFR/
ALK aberrations were found.
The molecular characteristics of the proband’s PEAC
were further evaluated using a miRNA profiling panel to
predict tumor origin. Figure 2 shows the heat map rep-
resentation of unsupervised clustering of 47 miRNAs in
the proband’s sample (“sample BO01”) compared to pri-
mary and metastatic tumors of NSCLC, CRC and pan-
creatic ductal adenocarcinoma (PDAC), and primary
gastric, kidney, prostate, skin, and liver cancers, as de-
scribed previously [15]. This profiling revealed striking
similarities with NSCLC (75.98 %) and a partial overlap
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Fig. 1 P1 Histological analyses (hematoxylin and eosin) revealed the presence of two different phenotypes in the lung lesion of the proband. We
found non-small cell lung cancer (NSCLC, 30 %; A magnification ×10; B magnification ×40) and pulmonary enteric adenocarcinoma (PEAC, 70 %;
C magnification ×10; D magnification ×40). Table 1 summarizes the marker expression associated with these two different phenotypes. The
expression of TTF1 and CDX2 was associated with NSCLC and PEAC, respectively. Strong expression of CK7 was observed in both phenotypes
(100 %). P2 Immunohistochemical signatures in NSCLC (left panels) and PEAC (right panels). TTF1 (A, B, C, and D); CK7 (E, F, G, and H); CDX2 (I, L,
M, and N); and CK20 (O, P, Q, and R) staining showing co-localizations of TTF1/CK7 and CDX2/CK7 in NSCLC and PEAC, respectively. Columns 1
and 3 (magnification ×10); columns 2 and 4 (magnification ×40). P3 Mucins (MUCs) expression in PEAC and pancreatic intraductal papillary
mucinous neoplasms (IPMNs). Strong coexpression of MUC1 and MUC5AC was observed in the area with PEAC histology. Conversely, in the
same area, we did no detect MUC2 expression. Examples of the positive expression of MUC1 (D), MUC2 (E), and MUC5AC (F) associated with
different subtypes of IPMNs. Columns 1 and 2 (magnification ×40). P4 Summary of mucins (MUCs) expression in the different subtypes of IPMNs
and in our PEAC samples showing similar molecular markers expression. In particular, the negative expression for MUC6 (data not shown)
suggests a pancreatobiliary differentiation of areas within our PEAC sample
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microarray data were confirmed by PCR analyses,
focusing on five miRNAs, which showed a similar
expression pattern in the proband’s brother (Additional
file 3: Figure S2).
Discussion
To our knowledge, this is the first study describing
PEACs in members of the same family, associated with
clinicopathological characteristics, histological, and gen-
etic findings. Recently, El Hammoumi et al. described a
patient with PEAC localized in the right lower lobe andassociated with primary CRC [13]. However, miRNA
profiling of the proband’s PEAC resembled that of lung
cancer, with partial overlap of PDAC, but not CRC. This
might at least in part explain the shorter disease-free
survival (DFS) in the proband and his sister (1.5 and
12 months, respectively) compared to radically resected
NSCLC patients, such as the 171 stage IA–IIIA NSCLC
patients evaluated by Park et al., with a median DFS of
20 months [16].
Notably, we observed two different phenotypes
(NSCLC and PEAC) in the lung lesions of the proband,
which differed in IHC staining for TTF-1 and CDX2
Fig. 2 Unsupervised cluster analysis of 47 miRNAs in the proband’s sample of PEAC (“sample BO01”) compared to primary and metastatic
tumors of lung cancer, CRC and PDAC, and also primary tumors of gastric, kidney, prostate, skin, and liver cancer. The colors represented on
the heat-map correspond to the normalized miRNA expression value: green indicates downregulation while red indicates upregulation referred to
the miRNA average value across all samples
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TTF-1 positivity and CDX2 negativity. Conversely, the
PEAC phenotype did not express the “lung cancer
marker” TTF-1 but was instead characterized by the
“intestinal marker” CDX2. Similar findings were ob-
served in the proband’s sister and brother, underlying
the potential role of these two markers (TTF-1,
CDX2). Conversely, the proband and his sister
showed different immunostaining for CK7 and CK20,
commonly utilized to separate colorectal from other
primary adenocarcinomas, especially the lung [12].
However, a previous description of 15 PEACs re-
ported positivity for CK7 and CK20 in 93 and 27 %
of cases, respectively [6].Genetic analyses revealed KRAS (Gly12Asp) mutations,
while no EGFR mutations or ALK rearrangements were
described, in agreement with previous studies [2–13].
Using a 47-miRNA diagnostic array, we found that the
miRNA profile of the proband’s PEAC was similar to
that of lung carcinomas, but not CRC. However, we
found a partial overlapping miRNA profile with PDAC,
sharing some key miRNAs associated with tumor ag-
gressiveness (miR-31*/-126*/-506/-508-3p/-514). In par-
ticular, miR-126*, mir-506, mir-508-3p, and mir-514 act
as tumor suppressor genes, and their downregulation
has been associated with proliferation, invasiveness, and
poor survival outcomes [17–22]. Furthermore, miR-31*
acts as oncogene and its’ overexpression was an
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MUCs expression in our PEACs compared to the differ-
ent subtypes of IPMNs suggest pancreatobiliary differen-
tiation and again, not intestinal, despite histological
similarity [24].
Qureshi et al. [8] described a patient affected by meta-
static PEAC, showing good response after 4 cycles with
carboplatin and pemetrexed. The same treatment was
associated with disease progression in our patient, while
his sister obtained disease stability after 6 cycles, sug-
gesting that further studies are needed to define if the
combination of platinum-based drugs and pemetrexed
can be used as an option for first-line treatment in
PEAC. Conversely, we do not recommend the CRC regi-
mens, since we observed disease progression after
XELOX, and the miRNA profiling showed no concord-
ance with CRC. Finally, we observed disease stabilization
after docetaxel, which is interesting, as taxanes showed
efficacy in both NSCLC and PDAC. On the basis of
these observations, as well as on the shorter DFS and
miRNA profiling, we presume that PEAC represents an
aggressive histological subtype of lung adenocarcinoma.
Therefore, building upon previous evidence on the key
role of histology and genetics to improve the management
of advanced NSCLC, especially lung adenocarcinoma, we
hypothesize that a better molecular understanding of
PEAC will boost future therapeutic options.
Ethics and consent
The research reported in the manuscript was performed
with the approval of the appropriate ethics committee.
Written informed consent was obtained for the molecular
analyses and publication of this study.
Additional files
Additional file 1: Analyses of EGFR, KRAS, ALK and MSI. Detailed
methods used for the analyses of EGFR, KRAS mutation, ALK
rearrangement, MSI, and miRNA-PCR. (DOC 108 kb)
Additional file 2: Supplemental Figure S1. Immunohistochemical
analyses in the cytological sample of the proband’s brother. The stainings
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patterns of protein expression similar to the expression levels observed
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